BOX Bolsters Box Sign Portfolio With FDA Part 11 Approval
https://www.zacks.com/stock/news/2212091/box-bolsters-box-sign-portfolio-with-fda-part-11-approval?cid=CS-ZC-FT-analyst_blog|company_news_tech_sector-2212091
Jan 18, 2024 - BOX receives FDA 21 CFR Part 11 approval for electronic signatures, facilitating research, development and manufacturing processes without incurring incremental costs.
0
Salesforce (CRM) Unveils GenAI-Powered Tools for Retailers
https://www.zacks.com/stock/news/2210013/salesforce-crm-unveils-genai-powered-tools-for-retailers?cid=CS-ZC-FT-analyst_blog|company_news_tech_sector-2210013
Jan 15, 2024 - Salesforce (CRM) brings generative AI to its Commerce Cloud and Marketing Cloud solutions, which is likely to help retail merchandisers optimize their business operations while enhancing shoppers' experience.
0
Are the "Magnificent Seven" Really That Great?
https://www.fool.com/investing/2024/01/13/are-the-magnificent-seven-really-that-great/?source=iedfolrf0000001
Jan 13, 2024 - We've also got a look at two stocks worth watching: UiPath and Pebblebrook Hotel Trust.
0
Infosys (INFY) Gains 4% as Q3 Earnings & Revenues Beat Estimates
https://www.zacks.com/stock/news/2209411/infosys-infy-gains-4-as-q3-earnings-revenues-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2209411
Jan 12, 2024 - Infosys' (INFY) better-than-expected Q3 performance reflects the benefits of strong sales executions and improved operational efficiencies.
0
The Zacks Analyst Blog Highlights Merck, Salesforce, Philip Morris International, Novartis and CME Group
https://www.zacks.com/stock/news/2206930/the-zacks-analyst-blog-highlights-merck-salesforce-philip-morris-international-novartis-and-cme-group?cid=CS-ZC-FT-press_releases-2206930
Jan 08, 2024 - Merck, Salesforce, Philip Morris International, Novartis and CME Group are part of the Zacks top Analyst Blog.
0
Top Analyst Reports for Merck, Salesforce & Philip Morris
https://www.zacks.com/commentary/2206306/top-analyst-reports-for-merck-salesforce-philip-morris?cid=CS-ZC-FT-research_daily-2206306
Jan 05, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Salesforce, Inc. (CRM) and Philip Morris International Inc. (PM).
0
Wall Street Analysts Think Salesforce.com (CRM) Is a Good Investment: Is It?
https://www.zacks.com/stock/news/2205636/wall-street-analysts-think-salesforce-com-crm-is-a-good-investment-is-it?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2205636
Jan 04, 2024 - Based on the average brokerage recommendation (ABR), Salesforce.com (CRM) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
0
24 Spectacular Stocks to Buy Hand Over Fist for 2024 (Including Growth Stocks and Dividend Stocks)
https://www.fool.com/investing/2023/12/30/24-spectacular-stocks-to-buy-hand-over-fist-for-20/?source=iedfolrf0000001
Dec 30, 2023 - Whether you're a growth stock investor or passive income investor, there is something for everyone in this list of top stocks to buy for 2024.
0
Here's Why Automatic Data (ADP) Deserves to be Retained Now
https://www.zacks.com/stock/news/2203329/here-s-why-automatic-data-adp-deserves-to-be-retained-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2203329
Dec 28, 2023 - Automatic Data (ADP) grows through strategic acquisitions and partnerships. Partnerships with Workday and Salesforce elevate HR interactions.
0
3 Magnificent Growth Stocks to Buy Right Now and Hold in 2024 and Beyond
https://www.fool.com/investing/2023/12/26/3-magnificent-growth-stocks-to-buy-right-now-and/?source=iedfolrf0000001
Dec 26, 2023 - You can build long-term wealth on Wall Street with these three magnificent stocks.
0